Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders
暂无分享,去创建一个
T. Takeuchi | K. Amano | C. Karyekar | T. Matsubara | H. Inoue | M. Iwahashi | Teruaki Nakano | T. Izumihara | A. Yamazaki | T. Kanamono | Takaaki Tanaka | Shoichi Uchimura
[1] T. Takeuchi,et al. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study , 2014, Modern rheumatology.
[2] H. Yamanaka,et al. AB0435 Effects of Prior Use of BIOLOGICS on the Safety and Effectiveness of Abatacept Administered with or without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Sub-Analysis of the Abatacept All-Cases Post-Marketing Surveillance , 2014 .
[3] D. M. van der Heijde,et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial , 2013, Annals of the rheumatic diseases.
[4] H. Hashimoto,et al. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study , 2013, Modern rheumatology.
[5] T. Takeuchi,et al. THU0125 A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intraveneous (IV) ABA in japanese rheumatoid arthritis patients with inadequate response to methotrexate , 2013 .
[6] M. Genovese,et al. Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study , 2013, Arthritis care & research.
[7] S. Nadler,et al. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. , 2013, Autoimmunity reviews.
[8] N. Miyasaka,et al. Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate , 2013, Modern rheumatology.
[9] D. M. van der Heijde,et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study , 2013, Arthritis and rheumatism.
[10] M. Weinblatt,et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis : two-year ef fi cacy and safety fi ndings from AMPLE trial , 2013 .
[11] J. Kremer,et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study , 2012, Annals of the rheumatic diseases.
[12] I. Strusberg,et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study) , 2011, Annals of the rheumatic diseases.
[13] M. Genovese,et al. Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate , 2011, Arthritis and rheumatism.
[14] M. Genovese,et al. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure , 2011 .
[15] A. Cope,et al. The central role of T cells in rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.
[16] H. Schellekens. Immunogenicity of therapeutic proteins. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] Stanley B. Cohen,et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.
[18] N. Rege,et al. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.
[19] N. N. Available. World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.
[20] H. V. van Lier,et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. , 1991, BMJ.